BRAF: which options do we have for these patients in second line?

10 / 22

BRAF INHIBITION IN mCRC
Regimen Response rate PFS Citation
Single/Doublet BRAF/MEK
Vemurafenib 5% 2.1 months Kopetz, ASCO ‘10
Dabrafenib 0% 4.5 Falchook, Lancet ’08
Encorafenib 0% 4 Gomez-Roca, ESMO ’14
Dabr + Tramet 12% 3.5 months Corcoran, ASCO ’14
Doublet with EGFR
Vem + Panit 13% 3.7 months Yeager et al. CCR ’14
Vem + Cetux 3.7% 3.2 months Tabernero et al. ASCO ’14
Encoraf + Cetux 19.2% 3.72 months Tabernero et al. ESMO GI ’16
Dabr + Panit 10% 3.5 months Corcoran, ESMO ‘16
Triplet with EGFR
Vem + Cetux + Irinotecan 16-35% 4.3-7.7 months Kopetz et al. ASCO GI ’17
Dabr + Tramet + Panit 21% 4.2 months Corcoran, ESMO ’16
Encoraf + Cetux + Alpelisib 17.9% 4.2 months Tabernero et al. ESMO GI ‘16
Sanz-Garcia E, et al. Ann Oncol 2017; 28(11):2648-2657.